UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

Cancer research (Chicago, Ill.), 2005-06, Vol.65 (12), p.5399-5407

2005

Volltextzugriff (PDF)

Improved tumor control through circadian clock induction by seliciclib, a cyclin-dependent kinase inhibitor

Cancer research (Chicago, Ill.), 2006-11, Vol.66 (22), p.10720-10728

2006

Volltextzugriff (PDF)

Antiviral Activity of CYC202 in HIV-1-infected Cells

The Journal of biological chemistry, 2005-01, Vol.280 (4), p.3029-3042

2005

Volltextzugriff (PDF)

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Lancet neurology, 2020-05, Vol.19 (5), p.402-412

2020

Volltextzugriff (PDF)

CDK inhibitors in clinical development for the treatment of cancer

Expert opinion on investigational drugs, 2003-06, Vol.12 (6), p.955-970

2003

Volltextzugriff (PDF)

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Journal of clinical oncology, 2014-06, Vol.32 (18), p.1919-1926

2014

Volltextzugriff (PDF)

Abstract CT111: Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT111-CT111

2021

Volltextzugriff (PDF)

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival

Blood, 2005-06, Vol.105 (11), p.4484-4491

2005

Volltextzugriff (PDF)

Phase I evaluation of seliciclib ( R -roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

European journal of cancer (1990), 2010-12, Vol.46 (18), p.3243-3250

2010

Volltextzugriff (PDF)

A Comparison of Ceftriaxone and Cefuroxime for the Treatment of Bacterial Meningitis in Children

The New England journal of medicine, 1990-01, Vol.322 (3), p.141-147

1990

Volltextzugriff (PDF)

Neuromyelitis optica spectrum disorder: Patient experience and quality of life

Neurology : neuroimmunology & neuroinflammation, 2019-07, Vol.6 (4), p.e580-e580

2019

Volltextzugriff (PDF)

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

The Lancet. Haematology, 2022-11, Vol.9 (11), p.e833-e843

2022

Volltextzugriff (PDF)

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

Expert opinion on investigational drugs, 2005-04, Vol.14 (4), p.457-477

2005

Volltextzugriff (PDF)

Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202

Journal of the American Society of Nephrology, 2004-05, Vol.15 (5), p.1212-1222

2004

Volltextzugriff (PDF)

Abstract 3028: PET imaging with the bispecific 89Zr-antibody ERY974 targeting CD3 and glypican 3 in tumor-bearing mouse models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3028-3028

2018

Volltextzugriff (PDF)

A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS2599-TPS2599

2018

Volltextzugriff (PDF)

A phase I dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3112-TPS3112

2017

Volltextzugriff (PDF)

A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS2592-TPS2592

2016

Volltextzugriff (PDF)

Efficacy and Safety of Satralizumab for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder: A Pooled Analysis from Two Phase 3 Clinical Trials

Multiple sclerosis and related disorders, 2020-01, Vol.37, p.101592, Article 101592

2020

Volltextzugriff (PDF)

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

Leukemia research, 2013-09, Vol.37 (9), p.1100-1106

2013

Volltextzugriff (PDF)

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course

Leukemia & lymphoma, 2014-09, Vol.55 (9), p.2114-2119

2014

Volltextzugriff (PDF)

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline

Blood, 2012-11, Vol.120 (21), p.46-46

2012

Volltextzugriff (PDF)

Final Results of a Phase Ib Trial of Atacicept to Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL)

Blood, 2009-11, Vol.114 (22), p.2373-2373

2009

Volltextzugriff (PDF)

Elacytarabine in relapsed/refractory acute myeloid leukaemia: An evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile

Leukemia research, 2014-03, Vol.38 (3), p.346-351

2014

Volltextzugriff (PDF)

Abstract C195: Phase I study of 2 dosing regimens of AS703569, an oral Aurora kinase inhibitor, in patients with solid tumors

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C195-C195

2009

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(17)
Humans
(15)
Adult
(9)
Female
(9)
Male
(9)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Aged
(7)
Middle Aged
(7)
Oncology
(7)
Adolescent
(6)
Purines - Pharmacology
(6)
Roscovitine
(6)
Hematology
(5)
Pharmacology. Drug Treatments
(5)
Transcription, Genetic - Drug Effects
(5)
Animals
(4)
Cyclin-Dependent Kinases - Antagonists & Inhibitors
(4)
Tumors
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

Improved tumor control through circadian clock induction by seliciclib, a cyclin-dependent kinase inhibitor

Antiviral Activity of CYC202 in HIV-1-infected Cells

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

CDK inhibitors in clinical development for the treatment of cancer

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Abstract CT111: Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival

Phase I evaluation of seliciclib ( R -roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

A Comparison of Ceftriaxone and Cefuroxime for the Treatment of Bacterial Meningitis in Children

Neuromyelitis optica spectrum disorder: Patient experience and quality of life

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202

Abstract 3028: PET imaging with the bispecific 89Zr-antibody ERY974 targeting CD3 and glypican 3 in tumor-bearing mouse models

A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors

A phase I dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors

A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors

Efficacy and Safety of Satralizumab for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder: A Pooled Analysis from Two Phase 3 Clinical Trials

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline

Final Results of a Phase Ib Trial of Atacicept to Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL)

Elacytarabine in relapsed/refractory acute myeloid leukaemia: An evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile

Abstract C195: Phase I study of 2 dosing regimens of AS703569, an oral Aurora kinase inhibitor, in patients with solid tumors

Suchergebnisse filtern